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Novel diagnostic techniques have been developed in many research area using targetable contrast
agents with magnetic resonance imaging (MRI) for cancer diagnosis. For cancer diagnosis, the
use of MRI with biocompatible targeting moieties and manganese ferrite nanoparticles (MFNPs)
is preferred. Thus, we synthesized MFNPs using a thermal decomposition method which enables
sensitive T2 or T2 Turbo Spin Echo (TSE) MRI and coated them with hyaluronic acid (HA). The
high targeting ability of HA-MFNPs was observed at MKN-45 cells (gastric cancer cell line) which
high-expressing C 44 in contrast with MKN-28 cells which l w-expr ssing CD44. We also prepared
the gastric cancer mice model using MKN-45 cells which h s the stem-like property was implanted
into BALB/c nude mice. And then HA-MFNPs of the T2 contrast enhancement effects and targeting
ability were investigated by in vivo MR imaging. As a result of these studies, we conclude that HA
coated MFNPs can be effectively used as a novel probes for visualizing gastric cancer stem cells.
Keywords: Contrast Agent, Gastric Cancer, CD44, Magnetic Nanoparticles, Magnetic
Resonance Imaging.
1. INTRODUCTION
Molecular imaging provides a tool to diagnose cancer
at the cellular and molecular levels. It not only allows
early and accurate tumor localization for diagnostic can-
cer imaging, but also has the potential to visualize the
biological processes of tumor growth, metastasis, and
response to treatment.1–10 Molecular magnetic resonance
(MR) imaging has emerged as a key tool in the diagno-
sis of cancer,10–16 since it has advantages over noninvasive,
anatomical imaging due to its high resolution, high con-
trast, and 3-dimensional information in real time, much
more so than nuclear medicine (positron electron tomog-
raphy and single-photon emission computed tomography)
and optical imaging.17–21 In addition, molecular MR imag-
ing is able to simultaneously detect the metabolism of
cells and tissues, physiological and structural information,
and biological processes occurring in deep tissues.2223
∗Authors to whom correspondence should be addressed.
Molecular MR imaging can be used to observe a variety
of lesions in the diagnosis of gastric cancer but also has
limitations.2425 In case of gastric cancer, it is difficult
to diagnose using MR imaging because many foods and
other digestive secretions exist inside the stomach.2426–29
Currently, many research groups are looking for a solu-
tion, but gastric cancer’s limitations and difficulties can be
addressed using various MR imaging contrast agents and
MR sequence.
Many MR contrast agents have been used for good
quality imaging.1330–34 However, the blood pool con-
trast agents cannot specifically reach their target goals.
Thus, we aim to develop a targetable contrast agent using
hyaluronic acid.35–41 In particular, hyaluronic acid is known
to interact with the CD44 receptor, and gastric cancer
is known to overexpress the CD44 receptor, a biomarker
of cancer stem cells.42–47 It is crucial for MR probes
to target early gastric cancer from a diagnostic point of
view. CD44 is important as a gastric cancer stem cell
marker as it interacts with hyaluronic acid. hyaluronic
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Scheme 1. Schematic illustration of hyaluronic acid-conjugated manganese ferrite nanoparticles (HA-MFNPs) for CD44-expressing gastric cancer
cell-specific MR imaging
acid is a nontoxic, biocompatible polymer, with tandem
disaccharide repeats of ß-1,4-D-glucuronic acid-ß-1,3-D-
N-acetylglucosamine; components of the glycosaminogly-
can family have been used in various areas as targeting
moieties for MR probes as well as antibodies.4148–53 In
addition, MRI sequence is also important in cancer diagno-
sis, In this study, molecular MR imaging was investigated
to find biological processes that occur in gastric cancer.
A T2 TSE sequence was used to confirm better diagnos-
tic possibilities and targeting effects were demonstrated
using hyaluronic acid-conjugated MFNPs (HA-MFNPs) in
a heterotopic xenograft gastric cancer model (Scheme 1).
Various experiments were conducted to evaluate specific




Polysorbate 80 (P80), ethylenediamine, 1,4-dioxane
(99.8%), and 1,1′-carbonyldiimidazole (CDI) were pur-
chased from Sigma Aldrich Chemical Co. Phosphate
buffered saline (PBS: 10 mM, pH 7.4), Roswell Park
Memorial Institute-1640 (RPMI-1640), fetal bovine serum
(FBS) and antibiotic-antimycotic solution were purchased
from Gibco and dialysis membrane (1 kDa MWCO)
from Spectrum laboratory. Hyaluronic acid (1 MDa) was
supplied from Yuhan Phrmaceutical Corporation (Seoul,
Korea). MKN-45 and MKN-28 (American Tissue Type
Culture) cell lines were grown in medium containing 10%
FBS and 1% antibiotic antimycotic at 37 C and a humid-
ified 5% CO2 atmosphere. Ultrapure deionized water was
used for all of the syntheses.
2.2. Synthesis of Manganese Ferrite
Nanoparticles (MFNPs)
The monodispersed MFNPs were prepared by ther-
mal decomposition method.54 Briefly, 2 mmol iron (III)
acetylacetonate, 1 mmol manganese (II) acetylacetonate,
10 mmol 1,2-hexadecanediol, 6 mmol dodecanoic acid,
and 6 mmol dodecylamine were dissolved in 20 mL ben-
zyl ether under an ambient nitrogen atmosphere. The mix-
ture was then preheated to 200 C for 2 h and refluxed at
300 C for 30 min. After the reactants were cooled to room
temperature, the products were purified with an excess of
pure ethanol. Approximately 11 nm MFNPs were synthe-
sized using the seed-mediated growth method.55
2.3. Preparation of HA-MFNPs
Aminated MFNPs were fabricated using the nano-
emulsion method. First, 30 mg of MFNPs was dissolved
in 4 ml of n-haxane (organic phase). The organic phase
was injected into 30 ml of de-ionized water (aqueous
phase) containing 100 mg of aminated P80. After mutual
saturation, the solution was emulsified for 20 min under
ultrasonification (ULH700S, Ulssohitech, Cheonwon-gum,
South Korea) at 450 W. The mixture was kept overnight at
room temperature to remove the volatile organic solvent.
The product were purified using a centrifugal filter (Cen-
triprep YM-3, 3-kDa molecular weight cutoff (MWCO),
Amicon, Millipore Corporation, Billerica, MA, USA) in
three times at 3,000 rpm for 20 min. HA-MFNPs were
fabricated by EDC-NHS chemistry. First, the pH of the
aminated MFNP solution was adjusted to neutral condi-
tion by the addition of 0.1 N HCl solution. Then, HA
(9.63 mol) were dissolved in the 40 ml of de-ionized
water followed by the addition of EDC and sulfo-NHS.
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Each HA solution was added to aminated MFNPs con-
taining 50 mg of MFNPs. The HA and aminated MFNPs
were reached for 2 h at room temperature. Finally, EDC,
sulfo-NHS, and unbound HA were removed using dialy-
sis (MWCO, 25,000) against excess de-ionized water. The
hydrodynamic diameter and zeta potential of HA-MFNPs
were analyzed by laser scattering (ELS-Z, Otsuka Elec-
tronics) and the relaxivity (R2) data of the HA-MFNPs
was obtained by MR imaging analysis.
2.4. Biocompatibility Tests for HA-MFNPs
The cytotoxic effects of HA-MFNPs in MKN-45 cells and
MKN-28 was evaluated by 3-(4,5- dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. MKN-45
and MKN-28 cells were maintained in RPMI-1640 con-
taining 10% FBS and 1% antibiotics at 37 C in a humid-
ified atmosphere with 5% CO2. MKN-45 and MKN-28
cells (1.0× 104 cells/well) were seeded into a 96-well
plate at 37 C overnight and the cells were incubated with
various concentrations of HA-MFNPs for 4 h. The cells
were washed with 100 L PBS (pH 7.4, 1 mM), and
100 L phenol red free RPMI-1640 was added. Subse-
quently, the cells were treated with MTT assay solution
according to the manufacturer’s instructions. Cell viabil-
ity was evaluated using a microplate reader (Synergy H4
hybrid reader, BioTek) at an absorbance wavelength of
575 nm (reference wavelength of 650 nm). Cell viabil-
ity was represented by normalization against HA-MFNPs-
non-treated cells (which were considered as having 100%
cell viability).
2.5. Darkfield Microscopy
MKN-45 and MKN-28 cells (2.0× 105 cells/well) were
seeded onto cover glass in 4 well plates and incubated
at for 4 h at 37 C. Prepared various concentrations of
HA-MFNPs were added to RPMI. After incubation for
48 h at 37 C, the cells were washed with PBS and fixed
with 4% paraformaldehyde. To observe HA-MFNPs in the
cells, the light scattering images were recorded using an
inverted microscope (Olympus BX51, Japan) with a highly
numerical darkfield condenser (U-DCW, Olympus), which
delivers a very narrow beam of white light from a tung-
sten lamp to the surface of the sample. Immersion oil (nd:
1.516, Olympus) was used to narrow the gap between the
condenser and the glass slide, and to balance the refractive
index.
2.6. Prussian Blue Staining
MKN-45 and MKN-28 cells (1.0× 106 cells/well) were
seeded into 6-well plates and incubated at 37 C. Pre-
pared various concentrations of HA-MFNPs were mixed
with RPMI-1640 and these mixtures were added to the
cells. After incubation for 4 h at 37 C, the cells were
washed with PBS and fixed with 4% paraformaldehyde.
The working solution was prepared by mixing 10% potas-
sium ferrocyanide and 20% HCl in equal amounts. The
working solution was added to the cells and incubated for
30 min at room temperature. The cells were washed with
PBS and stained with nuclear fast red solution (Sigma,
USA) for 30 min at room temperature. The cells were
observed using an optical system microscope (Olympus
BX51, Japan).
2.7. Heterotopic Animal Model and
Experimental Procedure
All animal experiments were conducted with the approval
of the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC) International. Female
BALB/c nude mice at 7–8 weeks of age were anesthetized
by intraperitoneal injection of a Zoletil/Rompun mixture
and 1.0×107 MKN-45 cells which suspended in 200 L
saline were implanted into the femoral region. After cancer
cell implantation, MR imaging was performed between 2
and 3 weeks. After in vivo MR imaging, MR imaging of
the harvested organ was also performed. In addition, the
extracted tumor tissues from tumor-bearing mice treated
with HA-MFNPs were frozen, sectioned, and stained using
Prussian blue. All stained tissue sections were analyzed
using a virtual microscope (Olympus BX51, Japan) and
Olyvia software.
2.8. MR Imaging
We performed solution and in vitro MR imaging experi-
ments with a 1.5 T clinical MRI instrument with a micro-
47 surface coil (Intera, Philips Medical Systems, Best,
The Netherlands). The R2 (T2 relaxation rate, 1/T2, s−1)
of the HA-MFNPs solution and HA-MFNPs-treated cells
(1×107) were measured by using the Carr-Purcell-
Meiboom-Gill (CPMG) sequence at room temperature
with the following parameters: TR = 10 sec, 32 echoes
with 12 msec even echo space, number of acquisitions= 1,
point resolution of 156×156 m, and section thickness of
0.6 mm. For the acquisition of T2-weighted MR images of
MFNPs solution and HA-MFNPs or HA-MFNPs-treated
cells, the following parameters were adopted: resolution
of 234× 234 m, section thickness of 2.0 mm, TE =
15 msec, TR= 400 msec, and number of acquisitions= 1.
The r2 (mM−1 s−1) is equal to the ratio of the R2 to
the HA-MFNPs concentration. And in vivo MR imaging
experiments were performed with a 3T Siemens clinical
MR imaging instrument using a human wrist coil with T2
TSE sequence (TR: 4,000 ms, TE: 114 ms, slice thickness:
1.0 mm, FOV read: 180 mm).
3. RESULTS AND DISCUSSION
3.1. Preparation of MFNPs and HA-MFNPs
To detect the target cancer cells in MR images using low
dose of contrast agent, the contrast agent should have the
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high magnetic susceptibility. Thus, we synthesized high
crystalline MFNPs (MnFe2O4) by the thermal decompo-
sition method as previously reported.54 It was reported
that the relaxivity coefficient of MnFe2O4 is approximately
150% larger than Fe3O4.
57 The targeting moiety is also
necessary for target specific MR imaging, thus we selected
hyaluronic acid to targeting CD44-overexpressed gastric
cancer cells. For the conjugation with hyaluronic acid,
the MFNPs were enveloped by aminated P80 using nano-
emulsion method. HA-MFNPs were synthesized using
EDC/sulfo-NHS cross-linker. The hydrodynamic diameter
of the aminated MFNPs and HA-MFNPs were determined
to be 76.0± 18.5 nm and 132.4± 33.4 nm, respectively
(Fig. 1(a)). In addition, the surface charge of the aminated
MFNPs also changed from 21.2± 1.1 mV to −159±
12 mV after conjugation of hyaluronic acid due to the
negative charge of carboxyl group of hyaluronic acid
(Fig. 1(a)). After the conjugation of hyaluronic acid and
the aminated MFNPs, the size slightly increased due to
the large molecular weight of hyaluronic acid (1 MDa).
The zeta potential was changed from the positive to neg-
ative after conjugation of hyaluronic acid because of the
negative charge of carboxyl structure of hyaluronic acid.
As shown in Figure 1(b), the characteristic band of
HA-MFNPs conjugates were verified by FT-IR spec-
tra, which exhibits O–H stretching at 3200–3400 cm−1,
C O stretching at 1100–1300 cm−1, CO–NH(amide)
bonds at 1630–1680 cm−1 and CH2 bending in HA at
1430–1470 cm−1. To assess the potential use of HA-
MFNPs as MR imaging agents, we performed MR imaging
analysis using HA-MFNPs, which exhibited the highest
Figure 1. Characterization of HA-MFNPs for molecular MR imaging. (a) Hydrodynamic diameter (gray bar) and zeta potential (black circle) of
aminated manganese ferrite nanoparticles (aminated MFNPs) and hyaluronic acid-conjugated MFNPs (HA-MFNPs), respectively. (b) Fourier transform
infrared spectra of HA (green line), MFNPs (red line) and HA-MFNPs (black line). (c) Cell proliferation assay of MKN-28 (CD44−), MKN-45 (CD44+)
cells after treatment of HA-MFNPs at several concentrations. (d) Table of R2 values and MR images for each Fe concentration of HA-MFNPs.
magnetic properties at the appropriate size to avoid retic-
uloendothelial system detection and prolong retention in
the circulation. In Figure 1(d), the T2-weighted MR image
exhibited a strong black color, which signified a decrease
in signal intensity for the thicker HA-MFNPs solution.
3.2. In Vitro Analysis of HA-MFNPs
The MTT assay was then performed, in which yellow
tetrazolium salt is reduced to purple formazan crystals in
metabolically active cells. The relative percentage of cell
viability was determined as the ratio of formazan intensity
in viable cells which treated with HA-MFNPs to the inten-
sity in non-treated (control) cells. As shown in Figure 1(c),
the in vitro cytotoxicity measured by MTT assay showed
that the viability of MKN-45 and MKN-28 cells was 80%
at a concentration of 4.1 g Fe+Mn/mL in HA-MFNPs.
For verifying specific targeting efficacy of HA-MFNPs,
darkfield microscopy and Prussian blue staining analy-
sis were carried out and MKN-45 (CD44 +) and MKN-
28 (CD44 −) cell lines were selected due to difference
of their CD44-expressing level. In Figure 2(a), darkfield
microscopy images demonstrated that HA-MFNPs dis-
played excellent binding to MKN-45 cells in comparison
with MKN-28 cells.
MKN-45 cells treated with HA-MFNPs exhibited bright
spots. Furthermore, MKN-28 cells treated with HA-
MFNPs exhibited a low number of bright spots, indi-
cating that cellular binding affinity was low. Darkfield
microscopy method is excluding the unscattered beam
from image. As a result, the field around the speci-
men is generally dark. However, nanoparticles under same
J. Nanosci. Nanotechnol. 16, 196–202, 2016 199
Delivered by Publishing Technology to: Yonsei University
IP: 165.132.14.104 On: Wed, 06 Jan 2016 04:53:37
Copyright: American Scientific Publishers
Molecular Imaging of CD44-Overexpressing Gastric Cancer in Mice Using T2 MR Imaging Lee et al.
Figure 2. In vitro microscopic analysis of MKN-28 (CD44 −) and MKN-45 (CD44 +) cells after treatment of HA-MFNPs. (a) darkfield microscopic
images of MKN-28 (CD44 −), MKN-45 (CD44 +) cells were incubated with 10 g/mL of HA-MFNPs in 4 h. (b) prussian blue staining images of
MKN-28 (CD44 −), MKN-45 (CD44 +) cells were treated with 40 g/mL of HA-MFNPs in 4 h. All scale bars are 5 m.
brightness were scattered more than cellular matrix, thus
they shine brightly like a white spots.
In Figure 2(b), the extent of intracellular uptake of
HA-MFNP in both MKN-45 and MKN-28 cells was
confirmed using microscopic images after Prussian blue
Figure 3. In vivo MR imaging of MKN-45 xenograft mouse model and histological analysis. (a) T2 TSE MR images of xenograft mouse model
after intravenous injection of HA-MFNPs. TR: 4,000 ms, TE: 114 ms, Slice thickness: 1.0 mm, FOV read: 180 mm, coil elements: wrist coil.
(b) R2/R2Pre-injection(%) graph verses time after intravenous injection of HA-MFNP respectively. (c) Prussian blue staining image of tumor in mouse
xenograft model. Right pictures are magnified image of 80 times from left.
staining. Prussian blue staining is a commonly used in
histopathology to detect the presence of iron in specimens.
Any ferric ion present in the specimens combines with the
ferrocyanide and results in the formation of a bright blue
color. As a result, one can confirm the presence of a small
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amount of iron contained in the nanoparticles in cells or
tissues. The transport of HA-MFNPs into MKN-45 cells
took place efficiently. In contrast, MKN-45 and MKN-28
cells treated with HA-MFNPs exhibited insignificant cel-
lular uptake. The small fractions of observed iron were
represented the nonspecific cellular binding of MFNPs.
3.3. In Vivo MR Imaging Analysis of HA-MFNPs
The xenograft mice model were prepared to heterotopic
tumor model, thus MKN-45 cells were implanted into
right thigh intrasubcutanously because it has some advan-
tages to observe the volume or morphology of the tumor
rather than orthotopic gastric cancer model. In Figure 3,
contrast enhancement in MR imaging was identified after
HA-MFNPs injection into xenograft mice model. In T2
TSE MR images, clear anatomic details were observed,
and there was no artifact due to a difference in suscep-
tibility. Initially, the center of the tumor instantly dark-
ened, and contrast enhancement at surrounding vessels
was simultaneously observed (Fig. 3(a)). Four hours after
intravenous injection of HA-MFNPs into the lateral tail
vein of the mice model, the T2-contrast enhancement
was observed at the tumor site. In contrast, in the MR
image of post-injection 30 min, the change of T2-signal
was not shown significantly. This result was re-confirmed
R2/R2Pre-injection(%) graph. We think this data demonstrate
that the HA-MFNPs have the ability of long c rculation
against of other T1 contrast agent.
3.4. Histological Analysis
In Figure 3(c), the histological morphology of tumor was
confirmed using H&E staining. We noticed that each of
the cancer cells could be observed through hematoxylin
(nucleus: blue) and eosin Y (cytoplasm: pink) staining.
Figure 3(c) shows that the iron content (black arrows) of
accumulated HA-MFNPs in the tumors was also observed
by Prussian blue staining. We thus confirmed that our
developed HA-MFNPs had an adequate capability for tar-
geting CD44-overexpressing gastric cancer.
4. CONCLUSIONS
In summary, we synthesized HA-MFNPs as MR imag-
ing agents for effective diagnoses of CD44-overexpressing
gastric cancer. Gastric cancer is difficult to diagnose using
MR imaging, but we tried to solve this problem by using
an HA-MNFP contrast agent. We plan to evaluate addi-
tional imaging tools using variable MR sequences for a
better imaging technique.
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